Epidarex Capital has raised over £48m to lead investments in early-stage life science and health technology companies, including spin-outs from research universities.
Global pharmaceutical company Eli Lilly and Company participated in the final closing with a significant capital commitment. King’s College London also invested in the final closing.
The fund’s early-stage focus is supported by a diverse range of investors, including four top research universities as well as the European Investment Fund, Scottish Enterprise and Strathclyde Pension Fund. Epidarex’s working relationship with the Universities of Edinburgh, Glasgow and Aberdeen, as well as with King’s College London, provides access to some of the most innovative healthcare start-ups, including those specialising in novel drug development.
‘The completion of our fund is a significant validation of the UK’s life science research base,’ said Sinclair Dunlop, managing partner at Epidarex Capital. ‘We have been delighted to attract a broad range of investors, including Lilly, one of the world’s most prestigious pharmaceutical firms. All of our investors are committed to the fund’s goal of providing the scalable capital needed to commercialise the UK’s most innovative research.’